Bildkälla: Stockfoto

Xbrane Biopharma: Framework Agreement with NHS - Redeye

Redeye reiterates its SEK173 base case following today’s announced Framework agreement with NHS and an eventful year ahead. We assess that it could generate more than SEK100m in royalties over the coming twelve months.

Redeye reiterates its SEK173 base case following today’s announced Framework agreement with NHS and an eventful year ahead. We assess that it could generate more than SEK100m in royalties over the coming twelve months.
Börsvärldens nyhetsbrev
ANNONSER